Blindness News and Research

RSS

Electrically stimulating nerve cells can restore some vision

Results: MIT engineers have designed a retinal implant for people who have lost their vision from retinitis pigmentosa or age-related macular degeneration, two of the leading causes of blindness. The retinal prosthesis would help restore some vision by electrically stimulating the nerve cells that normally carry visual input from the retina to the brain.

24 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

Gene variant discovery could lead to future glaucoma treatments

An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.

22 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Optimized diabetes management with the CONTOUR(R) USB blood glucose meter

Bayer Diabetes Care today announced U.S. Food & Drug Administration clearance to market the CONTOUR(R) USB blood glucose meter. Bayer's CONTOUR USB meter is the first and only blood glucose monitor that plugs directly into a computer providing users with instant access to information that can help optimize diabetes management. The CONTOUR USB meter is integrated with Glucofacts(TM) DELUXE software for easy retrieval of data as well as longer-term tracking and analysis of blood glucose test results.

21 Sep 2009

March of Dimes to re-launch Healthy Baby program for military families

Military moms whose babies were born too soon or too sick were treated to a very special baby shower today at the Portsmouth Naval Medical Center Neonatal Intensive Care Unit (NICU) courtesy of the March of Dimes and Operation Shower.

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Artificial vision enhancers to reach the market by 2011

Visually impaired or blind patients with degenerative retina conditions would be very happy if they were able to regain mobility, find their way around, be able to lead an independent life and to recognize faces and read again. These wishes were documented by a survey conducted by a research team ten years ago to find out what patients' expectations of electronic retina prostheses (retina implants) were.

19 Sep 2009

Findings may yield new treatments for visual disorders

By testing formerly blind patients within weeks of sight restoration, Sinha and his colleagues found that subjects had very limited ability to distinguish an object from its background, identify overlapping objects, or even piece together the different parts of an object. The patients gradually improved over time, and the new study suggests that dynamic information - that is, input from moving objects - is critical to the brain's ability to learn to segregate objects from their backgrounds (a task known as visual integration).

18 Sep 2009

Also in global health news: HIV/AIDS in Bangladesh; river blindness in Tanzania; potential immune system booster; compounds might fight TB

BDNews24.com reports on a new $13 million U.S.-government initiative aimed at "providing HIV-prevention services to two million at-risk people in Bangladesh including injecting drug users, male, female and transgender sex workers and their clients, and HIV-positive people through a network of 50 health centres." USAID will partner with Family Health International (FHI) to implement the program (9/17).

18 Sep 2009

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007.

17 Sep 2009

Also in Global Health news: Tanzania's health care; polio, diarrhea in India; ITNs in Nigeria; health in Sudan

Rotary International recently started working with the Indian government to fight diarrhea, which can make polio immunizations ineffective, IANS/Thaindian News reports. Deepak Kapur, chairman of the India National PolioPlus Society of Rotary International, said the plan is to educate people about the use of use of zinc tablets and oral rehydration therapy to prevent diarrhea, which kills almost 500,000 children per year in the country (Khan, 9/16).

17 Sep 2009

New technique found that may prevent vision loss

Blocking a protein that battles infection may help thwart a common cause of vision loss in chronic diseases such as diabetes, Medical College of Georgia researchers say.

16 Sep 2009

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).

14 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

1.4 million Nigerians over the age of 40 will become blind by 2020: Study

By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.

9 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009